A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Times Cited: 1450




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
3


Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2.
Maximilian Hopf, Christof Kloos, Gunter Wolf, Ulrich Alfons Müller, Nicolle Müller. J Clin Med 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
0

Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Susanne Jung, Agnes Bosch, Dennis Kannenkeril, Marina V Karg, Kristina Striepe, Peter Bramlage, Christian Ott, Roland E Schmieder. Eur Heart J Cardiovasc Pharmacother 2020
1



Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
2

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
2

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
5

Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
Michael Böhm, David Fitchett, Anne Pernille Ofstad, Martina Brueckmann, Stefan Kaspers, Jyothis T George, Isabella Zwiener, Bernard Zinman, Christoph Wanner, Nikolaus Marx,[...]. J Hypertens 2020
3

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

New and emerging cardiovascular and antihypertensive drugs.
Steven G Chrysant, George S Chrysant. Expert Opin Drug Saf 2020
1

The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi,[...]. Diabetes Care 2020
1

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Naro Ohashi, Taro Aoki, Takashi Matsuyama, Sayaka Ishigaki, Shinsuke Isobe, Tomoyuki Fujikura, Takuya Hashimoto, Daisuke Tsuriya, Hiroshi Morita, Akihiko Kato,[...]. Med Sci Monit 2020
1

SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Panagiotis I Georgianos, Maria Divani, Theodoros Eleftheriadis, Peter R Mertens, Vassilios Liakopoulos. Curr Med Chem 2019
2

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee,[...]. J Diabetes Investig 2019
9



Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
63

Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
5

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
Thea Anine Strøm Halden, Kine Eide Kvitne, Karsten Midtvedt, Laavanyaah Rajakumar, Ida Robertsen, Jan Brox, Jens Bollerslev, Anders Hartmann, Anders Åsberg, Trond Jenssen. Diabetes Care 2019
30


Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Ferruh Artunc. Cardiovasc Diabetol 2019
49

SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Jyotsana Pandey, Akhilesh K Tamrakar. Expert Opin Ther Pat 2019
6


The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
11

Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
Yu Ho Lee, Sang Hoon Kim, Jun Mo Kang, Jin Hyung Heo, Dong-Jin Kim, Seon Hwa Park, MinJi Sung, Jaehee Kim, Jisu Oh, Dong Ho Yang,[...]. Am J Physiol Renal Physiol 2019
19



Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
Bryce C Simes, Gordon G MacGregor. Diabetes Metab Syndr Obes 2019
10

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
76